• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    National Philanthropic Trust Welcomes Three Board Members

    1/3/24 9:30:00 AM ET
    $BANR
    $HLNE
    $OCGN
    Major Banks
    Finance
    Investment Managers
    Finance
    Get the next $BANR alert in real time by email

    Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth join the Board of Trustees at the largest national, independent donor-advised fund public charity

    National Philanthropic Trust (NPT), the largest national, independent public charity that manages donor-advised funds, and one of the leading grantmaking institutions in the U.S., is pleased to announce the appointment of Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth to its Board of Trustees.

    "As NPT continues to grow, innovate, and advance philanthropy around the world, we welcome these three accomplished professionals to our Board of Trustees," said Eileen Heisman, CEO of National Philanthropic Trust. "NPT is now the third largest grantmaking organization in the world. With esteemed careers in private market investing, technology, law, and philanthropy, Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth will make welcome additions to our board."

    Jeffrey Armbrister is an executive with more than 25 years of transaction-based investing and operational experience. He is the Chief Financial Officer of Hamilton Lane (NASDAQ:HLNE), a global private markets investment management firm.

    Armbrister previously served as the company's Global Head of Direct Equity Investments, where he was responsible for direction and oversight of the firm's direct equity and co-investment platform. His role included service on the boards of directors of companies in which Hamilton Lane invested on behalf of clients.

    Prior to joining Hamilton Lane, Armbrister served as Managing Director for Versa Capital Management, where he focused on making control-oriented, special situations, debt and equity investments in middle market companies across a variety of industries. While at Versa, he participated in all major investment functions, providing oversight for certain finance-related operational activities, including financial analysis and reporting and cash flow management for several portfolio companies.

    Prior to joining Versa, Armbrister was an Equity Research analyst at Oppenheimer + Close. He has also held private equity, venture capital, corporate development, and investment banking positions at Berwind Financial Group, Redleaf Group, ICG Commerce, and Wheat First Butcher Singer, respectively. He currently serves on the board of directors or similar bodies of several charitable organizations. Armbrister received his Bachelor of Arts in Economics from the University of Virginia.

    Lindy Benton-Moreno, an accomplished leader and sought-after speaker, has devoted her 30-year healthcare IT career to advancing technology and inspiring leaders. As an Executive Board Chair of Vyne, Benton-Moreno fueled the growth of a small dental company by establishing a thriving medical division.

    She was named by Health Data Management among the "Most Powerful Women in Healthcare IT" and recognized on Becker's "Women Power Players Health IT" list. As a Fellow at the Health Information and Management Systems Society, she engages with executive councils across health-related committees and industry associations.

    With a Master of Science from Florida State University, Benton-Moreno became a Distinguished Alumnus in Business and Industry, serving on the university's National Board of Directors as the university Alumni Association's National Director. Prior to entering healthcare IT, she pioneered the mainstreaming of 100+ children with disabilities into Florida's public schools and the sponsoring of scholarships for first-generation college students, an initiative close to her heart.

    Connie Collingsworth is an experienced board member with expertise in governance, risk management, executive compensation, and complex investments for publicly traded companies, private companies, and private equity funds. Her board experience includes leadership positions on public and private company boards as well as charitable organizations.

    Collingsworth's current board roles include Banner Corporation (NASDAQ:BANR) and Axxes Capital. She also serves as a Board Advisor to European private equity fund Planet First Partners, a Business Advisory Board Member to biotech company Ocugen (NASDAQ:OCGN), and a Strategic Advisor to venture fund LoudCapital.

    Collingsworth is the former Chief Operating Officer of the Bill & Melinda Gates Foundation, the largest private foundation in the world with over $65 billion in assets, distributing over $8.3 billion annually. During her 22-year tenure, she was responsible for managing and scaling the foundation's business operations globally. She also served as Chief Legal Officer, advising Bill Gates, Melinda French Gates, and Warren Buffett on governance, including creating the foundation's Governing Board. She was the architect of the foundation's IP philosophy and led the foundation's work in collaborating with for-profit companies, including big pharma and companies in the biotech and ed-tech sectors.

    Collingsworth holds a Master of Laws in International Business Studies from the University of Exeter, England, a Juris Doctorate from the University of Nebraska, and a Bachelor of Arts from Andrews University.

    About National Philanthropic Trust

    Founded in 1996, National Philanthropic Trust (NPT) is the largest national, independent public charity that manages donor-advised funds and one of the leading grantmaking institutions in the U.S. Since its founding, NPT has raised more than $49.8 billion in charitable funding and has made more than 640,000 grants exceeding $25.7 billion to nonprofits around the world. NPT annually publishes the Donor-Advised Fund Report, the sector's authority on the state of DAF philanthropy. Visit NPT's resource library to learn what you can do with a DAF and about NPT's impact investing options. More at NPTrust.org and NPTGivingPoint.org.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240103652385/en/

    Get the next $BANR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BANR
    $HLNE
    $OCGN

    CompanyDatePrice TargetRatingAnalyst
    Hamilton Lane Incorporated
    $HLNE
    4/16/2026$166.00Neutral → Overweight
    Analyst
    Ocugen Inc.
    $OCGN
    3/17/2026$12.00Buy
    Canaccord Genuity
    Ocugen Inc.
    $OCGN
    3/11/2026$10.00Outperform
    Oppenheimer
    Hamilton Lane Incorporated
    $HLNE
    12/11/2025$166.00Buy
    UBS
    Hamilton Lane Incorporated
    $HLNE
    11/6/2025$165.00Neutral → Buy
    Goldman
    Hamilton Lane Incorporated
    $HLNE
    10/14/2025$181.00Perform → Outperform
    Oppenheimer
    Hamilton Lane Incorporated
    $HLNE
    10/13/2025$150.00Mkt Perform → Outperform
    Keefe Bruyette
    Hamilton Lane Incorporated
    $HLNE
    10/3/2025$150.00Outperform
    BMO Capital Markets
    More analyst ratings

    $BANR
    $HLNE
    $OCGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hamilton Lane upgraded by Analyst with a new price target

    Analyst upgraded Hamilton Lane from Neutral to Overweight and set a new price target of $166.00

    4/16/26 7:58:32 AM ET
    $HLNE
    Investment Managers
    Finance

    Canaccord Genuity initiated coverage on Ocugen with a new price target

    Canaccord Genuity initiated coverage of Ocugen with a rating of Buy and set a new price target of $12.00

    3/17/26 8:33:47 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oppenheimer initiated coverage on Ocugen with a new price target

    Oppenheimer initiated coverage of Ocugen with a rating of Outperform and set a new price target of $10.00

    3/11/26 8:39:19 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BANR
    $HLNE
    $OCGN
    SEC Filings

    View All

    $BANR
    $HLNE
    $OCGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BANR
    $HLNE
    $OCGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BANR
    $HLNE
    $OCGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SEC Form S-4 filed by Banner Corporation

    S-4 - BANNER CORP (0000946673) (Filer)

    6/3/26 5:27:31 PM ET
    $BANR
    Major Banks
    Finance

    Ocugen Inc. filed SEC Form 8-K: Leadership Update

    8-K - Ocugen, Inc. (0001372299) (Filer)

    6/3/26 4:30:32 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Hamilton Lane Incorporated

    SCHEDULE 13D/A - Hamilton Lane INC (0001433642) (Subject)

    5/29/26 6:07:21 PM ET
    $HLNE
    Investment Managers
    Finance

    Executive Co-Chairman Rogers Hartley R. bought $9,992,338 worth of shares (110,932 units at $90.08) (SEC Form 4)

    4 - Hamilton Lane INC (0001433642) (Issuer)

    5/28/26 4:54:55 PM ET
    $HLNE
    Investment Managers
    Finance

    Director Berkman David J bought $1,010,000 worth of shares (10,000 units at $101.00) (SEC Form 4)

    4 - Hamilton Lane INC (0001433642) (Issuer)

    2/25/26 4:06:57 PM ET
    $HLNE
    Investment Managers
    Finance

    Co-Chief Executive Officer Hirsch Erik R. bought $988,260 worth of shares (9,225 units at $107.13), increasing direct ownership by 15% to 70,494 units (SEC Form 4)

    4 - Hamilton Lane INC (0001433642) (Issuer)

    2/24/26 4:07:41 PM ET
    $HLNE
    Investment Managers
    Finance

    Chief Operating Officer Kramer Andrea Anigati was granted 3,605 shares, increasing direct ownership by 4% to 86,067 units (SEC Form 4)

    4 - Hamilton Lane INC (0001433642) (Issuer)

    6/2/26 5:01:50 PM ET
    $HLNE
    Investment Managers
    Finance

    Chief Accounting Officer Carl Drew Thomas was granted 675 shares, increasing direct ownership by 58% to 1,846 units (SEC Form 4)

    4 - Hamilton Lane INC (0001433642) (Issuer)

    6/2/26 4:56:22 PM ET
    $HLNE
    Investment Managers
    Finance

    Chief Financial Officer Armbrister Jeffrey Brian was granted 2,109 shares, increasing direct ownership by 19% to 12,958 units (SEC Form 4)

    4 - Hamilton Lane INC (0001433642) (Issuer)

    6/2/26 4:48:51 PM ET
    $HLNE
    Investment Managers
    Finance

    Ocugen to Participate in Upcoming June Investor and Industry Conferences

    MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in June 2026. Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference Date: Thursday, June 4, 2026 Time: 2:30pm EDT Clinical Trials at the Summit 2026 Location: Fontainebleau Las VegasDate: Saturday, June 13, 2026Time: 10:19 – 10:39 am PDTInherited Retinal Diseases: Transforming the Future Through InnovationModerator: Peter KaiserPanelists: Lance Baldo, Pau

    6/2/26 7:03:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HAMILTON LANE INCORPORATED REPORTS FOURTH QUARTER AND FISCAL YEAR 2026 RESULTS

    CONSHOHOCKEN, Pa., May 21, 2026 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the fourth quarter and full fiscal year ended March 31, 2026. The Company issued a full detailed presentation of its fourth quarter and full fiscal year 2026 results, which can be accessed on the Company's Shareholders website at https://shareholders.hamiltonlane.com/.DividendHamilton Lane has declared a quarterly dividend of $0.60 per share of Class A common stock to record holders at the close of business on June 18, 2026 that will be paid on July 7, 2026. The target full-year dividend of $2.40 represents a 11% increase from t

    5/21/26 7:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    Cosette Pharmaceuticals Appoints David Bell as Chief Commercial Officer (Brands)

    — Proven biopharmaceutical executive to lead commercial strategy as Cosette scales its branded pharmaceutical platform and advances its next phase of growth — Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today it has appointed David Bell as Chief Commercial Officer (Brands). David joins the company's executive leadership team as it continues to advance its ambitions in specialty pharmaceuticals and expand its commercial platform and portfolio. In this new role, David will oversee all branded commercial functions – including sales, marketing, market access, commercial operations, analytics, and portfolio strategy. He will be responsible

    5/19/26 8:12:00 AM ET
    $HLNE
    Investment Managers
    Finance

    $BANR
    $HLNE
    $OCGN
    Leadership Updates

    Live Leadership Updates

    View All

    Cosette Pharmaceuticals Appoints David Bell as Chief Commercial Officer (Brands)

    — Proven biopharmaceutical executive to lead commercial strategy as Cosette scales its branded pharmaceutical platform and advances its next phase of growth — Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today it has appointed David Bell as Chief Commercial Officer (Brands). David joins the company's executive leadership team as it continues to advance its ambitions in specialty pharmaceuticals and expand its commercial platform and portfolio. In this new role, David will oversee all branded commercial functions – including sales, marketing, market access, commercial operations, analytics, and portfolio strategy. He will be responsible

    5/19/26 8:12:00 AM ET
    $HLNE
    Investment Managers
    Finance

    Banner Corporation to Acquire Pacific Financial Corporation

    Banner Corporation ("Banner") (NASDAQ:BANR), the holding company for Banner Bank, and Pacific Financial Corporation ("Pacific Financial") (OTCQX:PFLC), the holding company for Bank of the Pacific, today jointly announced that they have entered into a definitive merger agreement. Under the terms of the agreement, Banner will acquire Pacific Financial in an all-stock transaction, subject to the terms and conditions set forth therein. Following closing, the combined company is expected to have approximately $18 billion in assets. Bank of the Pacific is a 55-year-old Washington state-chartered commercial bank serving business and consumer clients at 18 branches and offices in Western Washingt

    4/30/26 6:00:00 PM ET
    $BANR
    Major Banks
    Finance

    Cosette Pharmaceuticals Appoints Erika Tooman as Senior Vice President, General Counsel, Strengthening Leadership Team to Drive Accelerated Growth and Strategic Expansion

    -- Experienced life sciences executive to lead legal, compliance, and governance as Cosette scales its platform following recent acquisitions and continued growth momentum -- Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today that it has appointed Erika Tooman as Senior Vice President and General Counsel, strengthening the company's executive leadership team as it advances its long‑term growth, portfolio expansion, and value‑creation strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429022652/en/ Erika brings more than two decades of experience guiding pharmaceutica

    4/29/26 8:15:00 AM ET
    $HLNE
    Investment Managers
    Finance

    $BANR
    $HLNE
    $OCGN
    Financials

    Live finance-specific insights

    View All

    HAMILTON LANE INCORPORATED REPORTS FOURTH QUARTER AND FISCAL YEAR 2026 RESULTS

    CONSHOHOCKEN, Pa., May 21, 2026 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the fourth quarter and full fiscal year ended March 31, 2026. The Company issued a full detailed presentation of its fourth quarter and full fiscal year 2026 results, which can be accessed on the Company's Shareholders website at https://shareholders.hamiltonlane.com/.DividendHamilton Lane has declared a quarterly dividend of $0.60 per share of Class A common stock to record holders at the close of business on June 18, 2026 that will be paid on July 7, 2026. The target full-year dividend of $2.40 represents a 11% increase from t

    5/21/26 7:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    Ocugen Provides Business Update with First Quarter 2026 Financial Results

    Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p<0.05) 31% reduction in lesion size and 27% EZ preservation (correlated to visual function) in optimal dose for Phase 3 About 20% of patients demonstrated no progression of disease and 75% of subjects showed > 30% reduction in Iesion growth compared to control, with a favorable safety and tolerability profileAllows robust registrational Phase 3 trial design, a potential combined U.S./EU trial with 300 subjects, with adaptive design powered at over 95% Trial enrollment complete for OCU400 for retinitis p

    5/5/26 8:32:54 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

    MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's first quarter 2026 financial results and provide a business update at 8:30 a.m. ET on Tuesday, May 5, 2026. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 4973685Webcast: Available on the events section of the Ocugen

    4/29/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BANR
    $HLNE
    $OCGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hamilton Lane Incorporated

    SC 13G/A - Hamilton Lane INC (0001433642) (Subject)

    11/13/24 9:56:40 PM ET
    $HLNE
    Investment Managers
    Finance

    Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

    SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

    11/12/24 4:59:47 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hamilton Lane Incorporated

    SC 13G/A - Hamilton Lane INC (0001433642) (Subject)

    11/12/24 3:55:46 PM ET
    $HLNE
    Investment Managers
    Finance